PGUK19093 / ANBL1821 / Andolina
Basic Study Information
Purpose:
This phase II trial studies how well irinotecan hydrochloride, temozolomide, and dinutuximab
work with or without eflornithine in treating patients with neuroblastoma that has
come back (relapsed) or that isn't responding to treatment (refractory). Drugs used
in chemotherapy, such as irinotecan hydrochloride and temozolomide, work in different
ways to stop the growth of tumor cells, either by killing the cells, by stopping them
from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies,
such as dinutuximab, may induce changes in the body's immune system and may interfere
with the ability of tumor cells to grow and spread. Eflornithine blocks the production
of chemicals called polyamines that are important in the growth of cancer cells. Giving
eflornithine with irinotecan hydrochloride, temozolomide, and dinutuximab, may work
better in treating patients with relapsed or refractory neuroblastoma.
Location: University of Rochester
Lead Researcher (Principal Investigator)
Lead Researcher:
Jeffrey Andolina
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search